Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Cerna, Olga
ROP-ET, NCT06514807: A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients	Active, not recruiting	3	117	Europe, RoW	Ropeginterferon alfa-2b (BESREMi®)	AOP Orphan Pharmaceuticals AG	Essential Thrombocythaemia	03/28	03/28
KER050-MD-201, NCT04419649 / 2021-001838-19: A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes Dec 2024 - Dec 2024 : Additional data for very low, low, or intermediate risk myelodysplastic syndrome Jul 2023 - Dec 2023 : Enrollment completion of transfusion dependent cohorts of trial for low, or intermediate risk MDS	Recruiting	2	140	Europe, US, RoW	KER-050	Keros Therapeutics, Inc., Keros Therapeutics, Inc.	Myelodysplastic Syndromes, Cytopenia	06/25	11/25
HALF, NCT04147533: Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia	Active, not recruiting	2	150	RoW	Imatinib withdrawal, Glivec withdrawal, Dasatinib, Sprycel withdrawal, Nilotinib, Tasigna withdrawal	Masaryk University	Chronic Myeloid Leukemia, Chronic Phase, Withdrawal;Drug	06/26	06/26
Jonasova, Anna
SENTRY, NCT04562389: Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022 Dec 2022 - Dec 2022: Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022 Dec 2022 - Dec 2022 : Data from trial in combination with ruxolitinib myelofibrosis Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022 Dec 2022 - Dec 2022: Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022 Data from P1 part of P1/2 XPORT-MF-034 trial for myelofibrosis at ASH 2022 Nov 2022 - Nov 2022: Data from P1 part of P1/2 XPORT-MF-034 trial for myelofibrosis at ASH 2022 Preliminary data from P1 part of P1/2 XPORT-MF-034 trial in combination with ruxolitinib for myelofibrosis at ASCO 2022 Jun 2022 - Jun 2022: Preliminary data from P1 part of P1/2 XPORT-MF-034 trial in combination with ruxolitinib for myelofibrosis at ASCO 2022 Data from P1 study in combination with ruxolitinib in 1L myelofibrosis at ASCO 2022 May 2022 - May 2022: Data from P1 study in combination with ruxolitinib in 1L myelofibrosis at ASCO 2022 More	Recruiting	3	330	Europe, Canada, US, RoW	Selinexor, KPT-330, Placebo, Ruxolitinib	Karyopharm Therapeutics Inc	Myelofibrosis	09/25	03/28
KER050-MD-201, NCT04419649 / 2021-001838-19: A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes Dec 2024 - Dec 2024 : Additional data for very low, low, or intermediate risk myelodysplastic syndrome Jul 2023 - Dec 2023 : Enrollment completion of transfusion dependent cohorts of trial for low, or intermediate risk MDS	Recruiting	2	140	Europe, US, RoW	KER-050	Keros Therapeutics, Inc., Keros Therapeutics, Inc.	Myelodysplastic Syndromes, Cytopenia	06/25	11/25
Sedlackova, Eva
No trials found